JP2025500482A5 - - Google Patents

Info

Publication number
JP2025500482A5
JP2025500482A5 JP2024538258A JP2024538258A JP2025500482A5 JP 2025500482 A5 JP2025500482 A5 JP 2025500482A5 JP 2024538258 A JP2024538258 A JP 2024538258A JP 2024538258 A JP2024538258 A JP 2024538258A JP 2025500482 A5 JP2025500482 A5 JP 2025500482A5
Authority
JP
Japan
Prior art keywords
saponin
bonds
linker
bond
ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024538258A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025500482A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/NL2022/050736 external-priority patent/WO2023121446A1/en
Publication of JP2025500482A publication Critical patent/JP2025500482A/ja
Publication of JP2025500482A5 publication Critical patent/JP2025500482A5/ja
Pending legal-status Critical Current

Links

JP2024538258A 2021-12-22 2022-12-20 筋消耗性障害の治療用の標的型サポニン-核酸コンジュゲート Pending JP2025500482A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL2030215 2021-12-22
NL2030215 2021-12-22
PCT/NL2022/050736 WO2023121446A1 (en) 2021-12-22 2022-12-20 Targeted saponin-nucleic acid conjugates for treatment of muscle wasting disorders

Publications (2)

Publication Number Publication Date
JP2025500482A JP2025500482A (ja) 2025-01-09
JP2025500482A5 true JP2025500482A5 (cg-RX-API-DMAC7.html) 2025-12-26

Family

ID=81585344

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024538258A Pending JP2025500482A (ja) 2021-12-22 2022-12-20 筋消耗性障害の治療用の標的型サポニン-核酸コンジュゲート

Country Status (11)

Country Link
US (1) US20250057971A1 (cg-RX-API-DMAC7.html)
EP (2) EP4610278A3 (cg-RX-API-DMAC7.html)
JP (1) JP2025500482A (cg-RX-API-DMAC7.html)
KR (1) KR20240121778A (cg-RX-API-DMAC7.html)
CN (1) CN118414172A (cg-RX-API-DMAC7.html)
CA (1) CA3240612A1 (cg-RX-API-DMAC7.html)
DK (1) DK4452331T3 (cg-RX-API-DMAC7.html)
ES (1) ES3052234T3 (cg-RX-API-DMAC7.html)
IL (1) IL313728A (cg-RX-API-DMAC7.html)
PT (1) PT4452331T (cg-RX-API-DMAC7.html)
WO (1) WO2023121446A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12370264B1 (en) 2018-08-02 2025-07-29 Dyne Therapeutics, Inc. Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
WO2020028832A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
EP3830259A4 (en) 2018-08-02 2022-05-04 Dyne Therapeutics, Inc. MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US20220023433A1 (en) * 2018-12-21 2022-01-27 Sapreme Technologies B.V. Saponin Conjugates
WO2021154477A1 (en) 2020-01-31 2021-08-05 Dyne Therapeutics, Inc. Anti-transferrin receptor (tfr) antibody and uses thereof
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
IL316143A (en) 2022-04-15 2024-12-01 Dyne Therapeutics Inc Muscle targeting complexes and formulations for the treatment of myotonic dystrophy
JP2026519131A (ja) * 2023-06-02 2026-06-11 サプリーム テクノロジーズ,ベー.フェー. 細胞内分子標的を介して作用する治療エフェクター成分のための改善された治療レジメン
WO2026087695A1 (en) 2024-10-24 2026-04-30 Sapreme Technologies B.V. Treatment for metabolic disorder
WO2026087680A1 (en) 2024-10-24 2026-04-30 Sapreme Technologies B.V. Treatment for cardiovascular disease
WO2026087678A1 (en) 2024-10-24 2026-04-30 Sapreme Technologies B.V. Treatment for renal disorders
WO2026119464A1 (en) 2024-12-03 2026-06-11 Sapreme Technologies B.V. Treatment for cns-related disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
WO2018080658A1 (en) 2016-10-27 2018-05-03 Aalborg University Therapeutic targeting of a microrna to treat duchenne muscular dystrophy
KR20240172236A (ko) 2017-01-06 2024-12-09 어비디티 바이오사이언시스 인크. 핵산-폴리펩티드 조성물 및 엑손 스키핑을 유도하는 방법
AU2019315593B2 (en) 2018-08-02 2026-05-21 Dyne Therapeutics, Inc. Muscle-targeting complexes and uses thereof
US20220023433A1 (en) 2018-12-21 2022-01-27 Sapreme Technologies B.V. Saponin Conjugates
JP7858532B2 (ja) 2020-01-10 2026-05-14 ダイン セラピューティクス,インコーポレーテッド 筋肉標的複合体および筋肉の健康に関連する遺伝子のモジュレーションのためのその使用

Similar Documents

Publication Publication Date Title
JP2025501610A5 (cg-RX-API-DMAC7.html)
ES3052234T3 (en) Targeted saponin-nucleic acid conjugates for treatment of muscle wasting disorders
JP2025500481A5 (cg-RX-API-DMAC7.html)
US20250082759A1 (en) Compositions comprising therapeutic nucleic acid and targeted saponin for the treatment of muscle-wasting disorders
US20250051770A1 (en) Compositions comprising therapeutic nucleic acid and saponin for the treatment of muscle-wasting disorders
KR20250004769A (ko) 근긴장성 이영양증을 치료하기 위한 근육 표적화 복합체 및 그의 용도
KR20250004771A (ko) 근긴장성 이영양증을 치료하기 위한 근육 표적화 복합체의 투여
AU2024312687A1 (en) Conjugates of saponin and antisense oligonucleotides for use in the treatment of neurodegenerative diseases
KR20260026556A (ko) 중추신경계 장애의 치료를 위한 약제학적 조성물
US20250205361A1 (en) Treatment regimens for therapeutic effector components that act via an intracellular molecular target
HK40118872A (en) Targeted saponin-nucleic acid conjugates for treatment of muscle wasting disorders
HK40118872B (en) Targeted saponin-nucleic acid conjugates for treatment of muscle wasting disorders
HK40110483B (en) Conjugate of saponin, oligonucleotide and galnac
HK40110483A (en) Conjugate of saponin, oligonucleotide and galnac
HK40091234A (en) Conjugate of saponin, oligonucleotide and galnac
HK40091234B (en) Conjugate of saponin, oligonucleotide and galnac